Cannabis-Related Stocks Aiming for New "Highs"
Karl Montevirgen of Halifax America LLC - InsideFutures.com - Tue Jan 02, 1:30PM CST

While cryptocurrencies might have dominated the financial media space in 2017, this year may see the emergence of yet another new industry: cannabis.

Although publicly traded cannabis stocks in the US have not quite achieved the same level of highs as their Canadian counterparts, for the simple reason that the latter has been operating with legal status as far back as 2001; perhaps getting a head start in terms of efficiency and profitability, the situation in the US may change as other states, including New Jersey, Ohio, Connecticut, Delaware and others, are now considering legalization for the recreational use of cannabis.

For now, here are a few stocks for Canadian cannabis-producing companies as well as US companies producing cannabis-derived or cannabis-supporting products.

Bear in mind that this is not a trading recommendation but a market alert for those who are interested in following this nascent industry.

Also, note that the figures below reflect the financial scenario at the time of this writing (Jan 2, 2018); links have been provided to view the updated figures.

Canopy Growth Corp TWMJF

Aphria APHQF

Aurora Cannabis ACBFF

MedReleaf MEDFF

AbbVie IncABBV

A pharmaceutical company that has several non-cannabis products, AbbVie has been developing a few cannabis-derived drugs. Their FDA-approved Marinol for instance, which contains forms of THC, is designed to help chemotherapy patients reduce nausea. Although cannabis-based drugs comprise a component of their total production, its important to note that AbbVie at the forefront of research for cannabis-based medications.

The Scotts Miracle-Gro Company SMG

One of the worlds largest producer/marketer of lawn and garden products, The Scotts Miracle-Gro Company is developing pesticides for use by marijuana growers.

INSYS Therapeutics, Inc INSY

Most recently, INSYS is undergoing phase 2 of its trial for a cannabis-derived solution for children with epilepsy. They are also known for developing the FDA-approved SYNDROS, a cannabinoid medicine to treat loss of appetite in AIDS patients and nausea and vomiting for chemotherapy patients.


The risk of loss in the trading of stocks, options, futures, foreign exchanges, foreign equities, and bonds can be substantial and is not suitable for all investors. Trading on margin or the use of leverage is not suitable for all investors and losses exceeding your initial deposit is possible. Supporting documentation is available upon request. Trading futures, options on futures, and foreign exchanges involves substantial risk of loss and is not suitable for all investors. Carefully consider whether trading is suitable for you in light of your circumstances, knowledge, and financial resources and only risk capital should be used. Opinions, market data, and recommendations are subject to change at any time. The lower the margin used the higher the leverage and therefore increases your risk. Past performance is not necessarily indicative of future results.